Stock Scorecard
Stock Summary for Summit Therapeutics Inc (SMMT) - $25.26 as of 5/12/2025 9:34:21 PM EST
Total Score
8 out of 30
Safety Score
40 out of 100
Currently on the following lists
None
Tim's Recommendation
Avoid
Growth List Algorithm Criteria for SMMT
| Positive earnings growth | |
| P/E ratio less than Industry P/E Ratio | |
| P/E ratio less than Sector P/E Ratio | |
| P/E ratio that is half the growth rate (or less) | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Positive net income past year and 12 trailing months | |
| Free cash flow ratio greater than 0 and less than 10 |
Small Cap List Algorithm Criteria for SMMT
| Revenue growing by at least 20% average per year over the last 5 years | |
| Market Capitalization under 2 billion | |
| Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months | |
| Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months | |
| Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year |
Dividend List Algorithm Criteria for SMMT
| Declared an ex-dividend date | |
| Forward annual dividend rate greater than 2 | |
| Positive net cash position the past year and most recent quarter | |
| Equity to debt ratio greater than 0.75 for past year and most recent quarter | |
| Current ratio most recent quarter greater than 2 | |
| Cash Flow per Share greater than Trailing Dividend Rate |
Bonus Criteria for SMMT
| P/E ratio less than five-year Average P/E ratio | |
| Last Price to 52 Week Low Ratio Less Than 1 | |
| Total Cash Per Share > Last Day Price | |
| P/S Ratio < 1 | |
| P/B Ratio < 1 |
Safety Rating Criteria for SMMT (40 out of 100)
| Stock Price Rating (Max of 10) | 7 |
| Historical Stock Price Rating (Max of 10) | 3 |
| Stock Price Trend (Max of 10) | 10 |
| Book Value (Max of 10) | 1 |
| Book Value to Price (Max of 10) | 0 |
| Analyst Buy Ratings (Max of 5) | 5 |
| Analyst Strong Buy Ratings (Max of 5) | 4 |
| Dividend Yield Percentage (Max of 10) | 0 |
| Operating Margin (Max of 10) | 0 |
| Trading Volume (Max of 10) | 10 |
| Price to Earnings (Max of 10) | 0 |
| Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) | 0 |
Latest News for for SMMT
Financial Details for SMMT
Company Overview |
|
|---|---|
| Ticker | SMMT |
| Company Name | Summit Therapeutics Inc |
| Country | USA |
| Description | Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and markets drugs to treat infectious diseases in the United States, Latin America, and Europe. The company is headquartered in Cambridge, Massachusetts. |
| Sector Name | LIFE SCIENCES |
| Industry Name | PHARMACEUTICAL PREPARATIONS |
| Most Recent Quarter | 3/31/2025 |
| Next Earnings Date | N/A |
Stock Price History |
|
| Last Day Price | 25.26 |
| Price 4 Years Ago | 2.69 |
| Last Day Price Updated | 5/12/2025 9:34:21 PM EST |
| Last Day Volume | 3,023,291 |
| Average Daily Volume | 5,610,297 |
| 52-Week High | 36.91 |
| 52-Week Low | 2.10 |
| Last Price to 52 Week Low | 1,102.86% |
Valuation Measures |
|
| Trailing PE | N/A |
| Industry PE | 30.10 |
| Sector PE | 47.92 |
| 5-Year Average PE | -71.01 |
| Free Cash Flow Ratio | 90.21 |
| Industry Free Cash Flow Ratio | 18.49 |
| Sector Free Cash Flow Ratio | 30.82 |
| Current Ratio Most Recent Quarter | 10.63 |
| Total Cash Per Share | 0.28 |
| Book Value Per Share Most Recent Quarter | 0.46 |
| Price to Book Ratio | 51.68 |
| Industry Price to Book Ratio | 35.42 |
| Sector Price to Book Ratio | 27.83 |
| Price to Sales Ratio Twelve Trailing Months | 753.90 |
| Industry Price to Sales Ratio Twelve Trailing Months | 89.39 |
| Sector Price to Sales Ratio Twelve Trailing Months | 25.47 |
| Analyst Buy Ratings | 6 |
| Analyst Strong Buy Ratings | 3 |
Share Statistics |
|
| Total Shares Outstanding | 742,666,000 |
| Market Capitalization | 18,759,743,160 |
| Institutional Ownership | N/A |
Dividends |
|
| Ex-Dividend Date | N/A |
| Previous Dividend Amount | 0.0000 |
| Current Dividend Amount | 0.0000 |
| Total Years Dividend Increasing | N/A |
| Trailing Annual Dividend Rate | 0.00 |
| Trailing Annual Dividend Yield | 0.00% |
| Forward Annual Dividend Rate | 0.00 |
| Forward Annual Dividend Yield | 0.00% |
| 5-Year Dividend Payments Count | 0 |
| 3-Year Average Dividend Yield | 0.00% |
| 5-Year Average Dividend Yield | 0.00% |
| 1-Year Dividend Growth Rate Percentage | 0.00% |
| 3-Year Dividend Growth Rate Percentage | 0.00% |
| 5-Year Dividend Growth Rate Percentage | 0.00% |
| All-Time Dividend Growth Rate Percentage | 0.00% |
| Dividend Payout Ratio | N/A |
Income Statement |
|
| Quarterly Earnings Growth YOY | 0.00% |
| Annual Earnings Growth | 64.01% |
| Reported EPS 12 Trailing Months | -0.34 |
| Reported EPS Past Year | -0.07 |
| Reported EPS Prior Year | -0.29 |
| Net Income Twelve Trailing Months | -240,755,000 |
| Net Income Past Year | -221,315,000 |
| Net Income Prior Year | -614,928,000 |
| Quarterly Revenue Growth YOY | -100.00% |
| 5-Year Revenue Growth | -100.00% |
| Operating Margin Twelve Trailing Months | 0.00% |
Balance Sheet |
|
| Total Cash Most Recent Quarter | 211,526,000 |
| Total Cash Past Year | 104,862,000 |
| Total Cash Prior Year | 71,425,000 |
| Net Cash Position Most Recent Quarter | 187,026,000 |
| Net Cash Position Past Year | 4,862,000 |
| Long Term Debt Past Year | 100,000,000 |
| Long Term Debt Prior Year | 100,000,000 |
| Total Debt Most Recent Quarter | 24,500,000 |
| Equity to Debt Ratio Past Year | 0.80 |
| Equity to Debt Ratio Most Recent Quarter | 0.93 |
| Total Stockholder Equity Past Year | 388,748,000 |
| Total Stockholder Equity Prior Year | 77,692,000 |
| Total Stockholder Equity Most Recent Quarter | 344,330,000 |
Free Cash Flow |
|
| Free Cash Flow Twelve Trailing Months | -173,544,843 |
| Free Cash Flow Per Share Twelve Trailing Months | -0.23 |
| Free Cash Flow Past Year | -142,245,000 |
| Free Cash Flow Prior Year | -76,888,000 |
Options |
|
| Put/Call Ratio | 0.17 |
| Has Options | Options Chain |
| Liquidity Rating | |
Technical Analysis |
|
| Yahoo Finance Chart | Yahoo Finance Chart |
| MACD | 1.20 |
| MACD Signal | 1.56 |
| 20-Day Bollinger Lower Band | 15.67 |
| 20-Day Bollinger Middle Band | 21.14 |
| 20-Day Bollinger Upper Band | 26.61 |
| Beta | -0.95 |
| RSI | 50.56 |
| 50-Day SMA | 17.25 |
| 150-Day SMA | 7.30 |
| 200-Day SMA | 6.48 |
System |
|
| Modified | 5/10/2025 10:30:42 AM EST |